Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatr Res ; 68(2): 169-73, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20485203

ABSTRACT

In a double-blind, randomized study, 136 children, 5-10-y-old, with newly detected persistent asthma received budesonide (BUD) 400 microg twice daily for 1 mo and thereafter 200 microg twice daily for 5 mo. Thereafter, 50 children were treated with BUD 100 microg twice daily, whereas 44 children used BUD as needed for 1 y; an additional 42 children received disodium cromoglycate (DSCG). Asthma exacerbations were treated with BUD for 2 wk in a dose of 400 microg twice daily in all groups. In this secondary analysis, bone mineral density (BMD) of the lumbar vertebrae was measured before and after the 18-mo treatment. Compared with DSCG, regular BUD treatment resulted in a significantly smaller increase in BMD (0.023 versus 0.034 g/cm; p = 0.023) and height (7.75 versus 8.80 cm; p = 0.001). Periodic treatment did not affect BMD. No intergroup differences were observed when BMD data were adjusted for changes in height. Daily BUD treatment in prepubertal children may slow down the increment in BMD and standing height. This was not observed in children receiving BUD periodically after the initial regular BUD treatment. The correlation between height and BMD suggests that following children's height might afford an estimation of inhaled corticosteroid effects on bone.


Subject(s)
Asthma/drug therapy , Bone Density/drug effects , Bronchodilator Agents/pharmacology , Bronchodilator Agents/therapeutic use , Budesonide/pharmacology , Budesonide/therapeutic use , Administration, Inhalation , Anti-Asthmatic Agents/administration & dosage , Anti-Asthmatic Agents/pharmacology , Anti-Asthmatic Agents/therapeutic use , Bronchodilator Agents/administration & dosage , Budesonide/administration & dosage , Child , Child, Preschool , Cromolyn Sodium/administration & dosage , Cromolyn Sodium/pharmacology , Cromolyn Sodium/therapeutic use , Double-Blind Method , Humans , Lumbar Vertebrae/anatomy & histology , Male
2.
Pediatr Res ; 67(2): 221-5, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19858777

ABSTRACT

In adults, asthma treatment with high doses of inhaled corticosteroids has resulted in dermal thinning. The aim of this study was to investigate the skin thickness in children with asthma during budesonide treatment. In a double-blind study, 113 children, 5-10 y old, with persistent asthma received budesonide 400 microg twice daily for 1 mo and thereafter 200 microg twice daily for 5 mo. Thereafter, 56 children received 100 microg twice daily for 1 y, whereas 57 other children used budesonide periodically for exacerbations. An additional 54 children were treated with disodium cromoglycate (DSCG) for 18 mo. Skin thickness was measured on each forearm before and after treatment for 6, 12, and 18 mo using a 20-MHz high-resolution ultrasonic device. The initial 6-mo budesonide treatment resulted in a greater reduction in mean skin thickness in the forearms compared with DSCG (right: -35.9 versus -5.9 microm; p = 0.004; left: -30.6 versus -7.3 microm; p = 0.03). At month 18, the inter-group differences were no longer significant. Budesonide inhalations in daily doses of 400-800 microg in prepubertal children with newly detected asthma may cause minor dermal thinning. The changes were reversible during low dose or periodic treatment with budesonide.


Subject(s)
Anti-Asthmatic Agents/administration & dosage , Asthma/drug therapy , Bronchodilator Agents/administration & dosage , Budesonide/administration & dosage , Skin/drug effects , Skinfold Thickness , Administration, Inhalation , Anti-Asthmatic Agents/adverse effects , Atrophy , Bronchodilator Agents/adverse effects , Budesonide/adverse effects , Child , Child, Preschool , Cromolyn Sodium/administration & dosage , Double-Blind Method , Drug Administration Schedule , Drug Therapy, Combination , Female , Finland , Forearm , Humans , Male , Severity of Illness Index , Skin/diagnostic imaging , Skin/pathology , Time Factors , Treatment Outcome , Ultrasonography
3.
Int Arch Allergy Immunol ; 128(4): 325-35, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12218371

ABSTRACT

BACKGROUND: Sensitivity to birch pollen allergens is a common feature among European patients with seasonal pollen allergy. In this in vitro study, we examined the specific serum IgE binding profiles to individual birch pollen allergens in birch-sensitive patients from six European populations. METHODS: The study included 242 patients from Finland, Sweden, Austria, France, Switzerland and Italy. All suffered from seasonal rhinoconjunctivitis and/or asthma. Their sera were analyzed for specific IgE reactivity to individual birch pollen allergens (recombinant Bet v 1, Bet v 2 and Bet v 4) and natural birch pollen extract using Pharmacia CAP System and immunoblotting. RESULTS: Almost all Finnish, Swedish and Austrian sera contained IgE specific for Bet v 1 (>or=98%). Bet v 1-specific IgE antibodies were found in 90% of the French sera, and in 65 and 62% of the sera from Switzerland and Italy, respectively. Few Finnish (2%) and Swedish (12%) patients had IgE to Bet v 2, while Bet v 2 reactivity was more common in the other populations (20-43%). Reactivity to Bet v 4 was rare in all populations (5-11%) except for the Italian patients, in whom 3 of 11 sera were positive (27%). The immunoblot results supported the specific IgE profiles obtained with Pharmacia CAP System showing a broader IgE reactivity profile in patients from central and southern Europe as compared to northern Europe. CONCLUSION: Component-resolved allergy diagnosis with recombinant allergens reveals that the IgE reactivity profiles to individual birch pollen allergens vary between European populations. This observation may be explained by sensitization to different allergen sources and will have an impact on allergen-specific prevention and therapy strategies.


Subject(s)
Allergens/immunology , Betula/immunology , Immunoglobulin E/immunology , Pollen/immunology , Rhinitis, Allergic, Seasonal/immunology , Adolescent , Adult , Aged , Allergens/genetics , Antibody Specificity , Antigens, Plant , Asthma/immunology , Calcium-Binding Proteins/genetics , Calcium-Binding Proteins/immunology , Child , Conjunctivitis, Allergic/immunology , Europe , Female , Humans , Immunoblotting , Male , Middle Aged , Plant Proteins/genetics , Plant Proteins/immunology , Recombinant Proteins/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...